Other information you can find at Online Pharmacy in Huntsville.
For anyone not familiar with the topic of Cymbalta withdrawal you may be surprised to find out than an astonishing amount of Americans are experiencing severe withdrawal symptoms once they try to stop taking Cymbalta. What is more infuriating than the withdrawal symptoms themselves is the fact that there is no information readily available to the public about Cymbalta withdrawal … expect of course on message boards and blogs.

Cymbalta which is an SNRI or Seretonin-norepinepherine reuptake inhibitor, is an antidepressant that is growing more and more popular. Eli Lilly, the manufacturer of Cymbalta recently received approval from the FDA for this drug to be prescribed to patient's experiencing neuropathy (nerve pain). Patient's that would fall into this category would be people with Diabetes of Fibromyalgia.

Because of this recent approval from the FDA, Cymbalta is now being deemed the “wonder drug”. It cures everything from depression to pain. So what's the problem? Cymbalta causes severe, dabilitating withdrawal symptoms in those who wish to stop taking it.

In an article I posted on my website titled Cymbalta Withdrawal Symptoms Suck I vented my frustration over experiencing Cymbalta withdrawal symptoms. In this article I explained that I had begun experiencing signs of illness including flu like symptoms, bone pain and the phenomena known as brain zaps. I was completely in the dark to the fact that these symptoms were in anyway related to me tapering off Cymbalta until I located some message boards filled with others experiencing the same exact thing.

To my astonishment my article about Cymbalta withdrawal has received hundreds of comments from other patient's experiencing all of the same sings and symptoms of Cymbalta withdrawal. This got me a little concerned and I started looking for some answers. My doctor couldn't provide any answers because according to him “he never heard of Cymbalta causing withdrawal”. I tried to find some information on the Cymbalta website but to my surprise…there is nothing mentioned about withdrawal symptoms.

So I have come to the conclusion that Cymbalta withdrawal only exists in cyberspace on message boards and blogs. This needs to change. The subject of Cymbalta withdrawal needs to be brought into the spotlight. There are people out there staying on Cymbalta for the sole purpose of avoiding withdrawal symptoms, not because they are getting any benefit from taking it.

So What Can We Do?

I have created an online Cymbalta petition which is addressed to Eli Lilly. It is a demand that they disclose any and all information they have about Cymbalta withdrawal to the public. People are unable to make informed decisions about whether or not to start taking Cymbalta if they don't have all the facts. I also ask that they make it mandatory that their pharmaceutical reps disclose information about Cymbalta's potential for causing withdrawal to physicians prior to handing out free samples. Finally, I asked that they provide a tapering down schedule that would make it possible to avoid/minimize the withdrawal symptoms and that this tapering schedule should be available to both physician and patient.

I am urging anyone and everyone to sign this online petition. It is open for signatures until February of 2008 at which time it will be delivered directly to Eli Lilly.

Secondly I have filed a formal complaint with the FDA advising them of exactly what withdrawal symptoms I experienced once I stopped taking Cymbalta. I am sending out a call for action to anyone who has suffered through Cymbalta withdrawal to also file a formal complaint with the FDA using their online reporting system.

Change happens because we make it happen.

Last news onmen's health

Long before the earthquake demolished what was left of parts of Haiti, the country's destitution could be seen from the air. Juxtaposed beside the green Dominican Republic, which occupies the other half of the island of Hispaniola, Haiti appears as a barren wasteland, a real-time before and after shot demarcated abruptly at the border. It is estimated that less than two per cent of Haiti's original tropical forest cover remains today, the result of centuries of overcutting. The overhead view is a tragic illustration of the environmental price of forestation, which renders even more desperate the human price on the ground.

In 2008, I had the privilege of witnessing the work of a group called the Flying Doctors, who were spending a week setting up portable day clinics in the Dominican Republic. They needed a French translator to travel with them to the bateyes – communities of Haitian migrant workers, who come to the Dominican Republic during the sugar cane and banana harvests to work as laborers. I was in the DR on high school educational outreach program, working in an impoverished community not far from the Haitian border. The Dominican Republic ranks 90th on the UN's World Poverty Index. According to the World Bank, fifteen per cent of the population lives in poverty, and there are skyrocketing rates of the twin scourges of desperate populations: illiteracy and malnutrition. And then I saw the Haitians.

Men, women and their children waited for hours, crowding the waiting room of the free clinic. Many had never seen a doctor. My French was only marginally useful faced with the Haitian Creole spoken there, but we made-do, and soon I got the gist as the doctors saw patient after patient. An eighty year-old man suffering from headaches all his life. We listened, performed a lengthy examination, and sent him away with Tylenol. His problem? He had no access to eyeglasses. Ever. There were teenagers with urinary infections, and men with venereal diseases, and hernias. There were tapeworms, scabies, common colds, menstrual cramps, and a baby with whooping cough. Several women came into the makeshift office and wept. They wanted their hand held, and spoke of sadness, hopelessness, fatigue and headaches. It was textbook depression, the same that women with children everywhere feel when they are overwhelmed, but these women didn't have the luxury of Cymbalta or group therapy.

And then there was Junior. He was a handsome twenty year-old, and that day he complained of, I believe, a sore knee or back, and the doctor thought he may have pulled a hamstring. He was lean and muscular and said he was a hard worker. I believed him. He could not get himself to whine about the life he was leading, the walk he made to and from work every day, the heat and fatigue. He was an optimist – the kind of person any boss would love to have on their team. He was removed from his home and family in Haiti, but he told me of his dream to play professional soccer, and he saw opportunity in working at the batey. I admired his Sean John sweatshirt, and I asked him if I could take his picture. He flashed a GQ smile and obliged.

I have been thinking of Junior a lot these days; his photo disappeared during some computer mishap. I hope he was in the relative safety of the Dominican Republic during the earthquake. Meanwhile, doctors and nurses and people with real skills continue to work day and night in Haiti, and engineers, architects and social workers will do the same to 'rebuild' what was in already in tatters, even before the storm. There was little infrastructure to build a society on, little opportunity for prosperous futures, and no vegetation to thwart the power of tropical storms. But my too-brief window into the Haitian people showed me what those on the ground who have been helping in Haiti for years, already know. There are people like Junior, who remain full of hope, undamaged by what can only be seen as a run of very bad luck.

Eli Lilly (LLY), the pharmaceutical behind Prozac for depression and Cialis for erectile dysfunction, is expected to post solid fourth-quarter profits on Thursday after a recent restructuring. But the results will likely be lower than the year-ago quarter. Analysts expect earnings of 91 cents per share on $5.64 billion in sales. In the same quarter last year, the company lost $3.31, due to costs associated with its ImClone acquisition, on revenue of $5.21 billion. Excluding charges related to the acquisition, Lilly reported a profit of $1.07 per share in the year-ago quarter.

For the full year, Lilly guided earnings in the range of $4.30 to $4.40 per share. As for 2010, Lilly raised its earnings forecast at December's annual meeting to between $4.65 to $4.85 a share, noting that the company expects its upcoming pipeline of drugs to offset expiration of several drug patents. Analyst expectations are for $4.73 a share. The company also said it expects 2010 revenue to rise in the high single digits on a percentage basis.

No Acquisition Spree

John Lechleiter, Lilly's president and CEO, said that unlike many of its competitors, Lilly hasn't embarked on an acquisition spree to tackle the fact that patents for drugs are expiring. By 2013, drugs representing more than half of the company's revenue, including the antipsychotic blockbuster Zyprexa, will lose patent protection and face generic competition. Instead of acquisitions, Lechleiter said the company will focus on its own pipeline.

“We currently have more than 60 new molecules in clinical development, including 25 in Phases II and III, targeting unmet medical needs in areas such as Alzheimer's disease, cancer and diabetes, among others,” said a Lilly executive Steven Paul.

The company recently refocused its operations around five business units: Oncology, diabetes, established markets, emerging markets and animal health. In its biggest segment, established markets, Lilly relies on Zyprexa, pain killer Cymbalta, erectile dysfunction drug Cialis and acute coronary syndrome med Effient. The pipeline includes molecules for Alzheimer's, arthritis and schizophrenia, among others. It's important to note that Zyprexa may find itself under FDA review following recent studies regarding weight gain in kids.

Budding Oncology Powerhouse

With the acquisition of ImClone and the progression of its own pipeline, Lilly claims it is well along the way to building an oncology powerhouse. Lilly's three key cancer medicines — Alimta, Gemzar and Erbitux — account for 14% of the company's worldwide revenue. Lilly also has 23 assets in its oncology pipeline, including two melanoma hopefuls.

Lilly's diabetes segment may soon get a boost as its Byetta once-weekly drug just got that much closer to approval after a similar Novo Nordisk's (NVO) new once-daily injection was approved. Other than a promising pipeline, Lilly has established products in the segment, although Byetta has met with some resistance.

Lilly also aims to increase its presence the so-called “pharmerging markets” — China, Russia, Brazil, Mexico, South Korea and Turkey — over the next decade.

Expected to Deliver

As for what the earnings announcement holds, according to Derica Rice, Lilly's senior VP and CFO, “Lilly is completing another year of strong operating performance, delivering solid earnings growth resulting from volume-based sales growth, improving gross margins and tightening control of operating expenses.”

So Lilly will likely deliver when it reports, but the question is whether it can sell investors on its pipeline and business plan, which includes reducing its cost structure by the end of 2011 by $1 billion. Over the past year, LLY shares significantly underperformed their peers and general market. With just a little bit of good news, they might just get jolted higher.
Buy Lipitor at Online Pharmacy in Green Bay.